{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": -0.5565919, "regularMarketPrice": 214.4, "exchange": "FRA", "shortName": "AMGEN INC.  DL-,0001", "longName": "Amgen Inc.", "messageBoardId": "finmb_24816", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "marketState": "REGULAR", "esgPopulated": false, "sharesOutstanding": 534327008, "bookValue": 10.009, "fiftyDayAverage": 219.827, "fiftyDayAverageChange": -5.427002, "fiftyDayAverageChangePercent": -0.024687605, "twoHundredDayAverage": 241.41925, "twoHundredDayAverageChange": -27.019257, "twoHundredDayAverageChangePercent": -0.111918405, "marketCap": 116180566016, "priceToBook": 21.420721, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 946882800000, "priceHint": 2, "regularMarketChange": -1.2000122, "regularMarketTime": 1683893255, "regularMarketDayHigh": 214.4, "regularMarketDayRange": "212.6 - 214.4", "regularMarketDayLow": 212.6, "regularMarketVolume": 25, "regularMarketPreviousClose": 215.6, "bid": 213.8, "ask": 214.2, "bidSize": 300, "askSize": 300, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 212.6, "averageDailyVolume3Month": 190, "averageDailyVolume10Day": 331, "fiftyTwoWeekLowChange": 8.0, "fiftyTwoWeekLowChangePercent": 0.03875969, "fiftyTwoWeekRange": "206.4 - 293.8", "fiftyTwoWeekHighChange": -79.399994, "fiftyTwoWeekHighChangePercent": -0.27025187, "fiftyTwoWeekLow": 206.4, "fiftyTwoWeekHigh": 293.8, "earningsTimestamp": 1682627400, "earningsTimestampStart": 1690973940, "earningsTimestampEnd": 1691409600, "trailingAnnualDividendRate": 7.95, "trailingPE": 16.181131, "trailingAnnualDividendYield": 0.03687384, "epsTrailingTwelveMonths": 13.25, "symbol": "AMG.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "One Amgen Center Drive", "city": "Thousand Oaks", "state": "CA", "zip": "91320-1799", "country": "United States", "phone": "805 447 1000", "fax": "805 447 1010", "website": "https://www.amgen.com", "industry": "Drug Manufacturers\u2014General", "industryDisp": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00e7et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.", "fullTimeEmployees": 25200, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert A. Bradway", "age": 59, "title": "Chairman, CEO & Pres", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 5487475, "fmt": "5.49M", "longFmt": "5,487,475"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 43693576, "fmt": "43.69M", "longFmt": "43,693,576"}}, {"maxAge": 1, "name": "Mr. Peter H. Griffith", "age": 63, "title": "Exec. VP & CFO", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": {"raw": 2574004, "fmt": "2.57M", "longFmt": "2,574,004"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 245771, "fmt": "245.77k", "longFmt": "245,771"}}, {"maxAge": 1, "name": "Mr. Esteban  Santos", "age": 54, "title": "Exec. VP of Operations", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 2521941, "fmt": "2.52M", "longFmt": "2,521,941"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 8232750, "fmt": "8.23M", "longFmt": "8,232,750"}}, {"maxAge": 1, "name": "Dr. David M. Reese M.D.", "age": 59, "title": "Exec. VP of R&D", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 2833393, "fmt": "2.83M", "longFmt": "2,833,393"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 4932458, "fmt": "4.93M", "longFmt": "4,932,458"}}, {"maxAge": 1, "name": "Mr. Murdo  Gordon", "age": 55, "title": "Exec. VP of Global Commercial Operations", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 2717562, "fmt": "2.72M", "longFmt": "2,717,562"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 2469817, "fmt": "2.47M", "longFmt": "2,469,817"}}, {"maxAge": 1, "name": "Ms. Linda H. Louie", "title": "VP of Fin. & Chief Accounting Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mike  Zahigian", "title": "Sr. VP & Chief Information Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Arvind  Sood", "title": "VP of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jonathan P. Graham", "age": 61, "title": "Exec. VP, Gen. Counsel & Sec.", "yearBorn": 1961, "fiscalYear": 2019, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Nancy A. Grygiel", "age": 54, "title": "Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 3, "boardRisk": 8, "compensationRisk": 1, "shareHolderRightsRisk": 1, "overallRisk": 1, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}